The Royal Marsden has announced the launch of MyTrack™ Myeloma, the world’s first fully integrated patient pathway for multiple myeloma.
This innovative, patient-centred approach brings together leading-edge innovation in advanced diagnostics and clinical expertise to transform how multiple myeloma is understood, monitored, managed and treated, with the goal of significantly improving the patient experience.
The MyTrack Myeloma pathway is initially available to private patients, with Bupa the first health insurer to cover the treatment for its customers with cancer cover. The Royal Marsden’s ambition Is to work with the NHS to bring this pioneering pathway to more patients in the future.
Multiple myeloma is an incurable cancer of the plasma cells, with around 6,000 people diagnosed every year in the UK. Outcomes for patients with multiple myeloma have improved significantly in recent years due to advances in drug therapies, however, despite being treatable, multiple myeloma remains incurable with patients requiring ongoing maintenance therapy. Current treatments are typically continuous and lifelong and may not always reflect the individual biology of a patient’s disease.
Patient communities worldwide have consistently highlighted the importance of more personalised approaches to care – including the possibility of treatment breaks, which can improve quality of life and reduce side effects from ongoing therapy.
However, standard diagnostic tools do not always provide sufficient insight into the cancer’s behaviour, such as aggressiveness, likelihood of relapse, or suitability for treatment pauses. As multiple myeloma varies widely between patients, identifying those who may safely benefit from treatment breaks requires precise tumour profiling and highly sensitive monitoring. MyTrack Myeloma addresses this gap by integrating advanced diagnostic technologies into a single, coordinated pathway.
Professor Martin Kaiser, Consultant Haematologist at The Royal Marsden NHS Foundation Trust and Professor in Molecular Haematology at The Institute of Cancer Research, London said: “Patients with multiple myeloma can remain on treatment for more than ten years. By incorporating advanced diagnostic tools, clinicians can gain a much clearer understanding of a patient’s cancer from the outset, enabling more personalised and effective first-line treatment, ensuring patients receive the right treatment at the right time These tools can also support more precise monitoring, creating opportunities to de-escalate or even pause treatment safely for some patients.”
The MyTrack Myeloma diagnostic pathway and associated tests will be available from early summer 2026.
For further information, including pricing details and how to request tests, please contact ClinicalGenomics_PP@rmh.nhs.uk or visit royalmarsden.nhs.uk/MyTrackMyeloma
Back
